Credit Suisse’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $7.91M | Sell |
182,509
-7,213
| -4% | -$344K | 0.01% | 1039 |
|
|
2023
Q4 | $9.6M | Sell |
189,722
-40,621
| -18% | -$1.95M | 0.01% | 946 |
|
|
2023
Q3 | $10.4M | Sell |
230,343
-14,639
| -6% | -$604K | 0.01% | 885 |
|
|
2023
Q2 | $10.1M | Buy |
244,982
+2,911
| +1% | +$112K | 0.01% | 928 |
|
|
2023
Q1 | $8.65M | Buy |
242,071
+57,769
| +31% | +$2.17M | 0.01% | 997 |
|
|
2022
Q4 | $6.96M | Buy |
184,302
+29,604
| +19% | +$1.25M | 0.01% | 1105 |
|
|
2022
Q3 | $6.84M | Buy |
154,698
+4,977
| +3% | +$210K | 0.01% | 1091 |
|
|
2022
Q2 | $5.54M | Sell |
149,721
-30,905
| -17% | -$1.17M | 0.01% | 1217 |
|
|
2022
Q1 | $6.69M | Buy |
180,626
+3,859
| +2% | +$126K | 0.01% | 1270 |
|
|
2021
Q4 | $5.38M | Sell |
176,767
-5,895
| -3% | -$186K | ﹤0.01% | 1958 |
|
|
2021
Q3 | $6.13M | Buy |
182,662
+23,477
| +15% | +$885K | ﹤0.01% | 1901 |
|
|
2021
Q2 | $6.35M | Buy |
159,185
+26,191
| +20% | +$1.03M | ﹤0.01% | 1900 |
|
|
2021
Q1 | $5.98M | Sell |
132,994
-11,894
| -8% | -$663K | ﹤0.01% | 1931 |
|
|
2020
Q4 | $8.19M | Sell |
144,888
-23,155
| -14% | -$1.15M | ﹤0.01% | 1715 |
|
|
2020
Q3 | $7.97M | Sell |
168,043
-8,044
| -5% | -$447K | ﹤0.01% | 1503 |
|
|
2020
Q2 | $10.4M | Buy |
176,087
+41,456
| +31% | +$2.31M | 0.01% | 1272 |
|
|
2020
Q1 | $6.37M | Buy |
134,631
+8,198
| +6% | +$457K | 0.01% | 1411 |
|
|
2019
Q4 | $7.64M | Buy |
126,433
+19,558
| +18% | +$1.17M | 0.01% | 1573 |
|
|
2019
Q3 | $6.4M | Sell |
106,875
-164,922
| -61% | -$10.7M | 0.01% | 1577 |
|
|
2019
Q2 | $17.5M | Sell |
271,797
-77,522
| -22% | -$5.48M | 0.02% | 993 |
|
|
2019
Q1 | $28.4M | Sell |
349,319
-157,559
| -31% | -$10.2M | 0.03% | 669 |
|
|
2018
Q4 | $27.4M | Sell |
506,878
-49,618
| -9% | -$2.53M | 0.03% | 622 |
|
|
2018
Q3 | $28.7M | Buy |
556,496
+9,430
| +2% | +$443K | 0.03% | 684 |
|
|
2018
Q2 | $22.8M | Sell |
547,066
-207,745
| -28% | -$9.21M | 0.02% | 769 |
|
|
2018
Q1 | $33.3M | Buy |
754,811
+301,872
| +67% | +$15.3M | 0.03% | 594 |
|
|
2017
Q4 | $22.8M | Buy |
452,939
+138,275
| +44% | +$7.58M | 0.02% | 814 |
|
|
2017
Q3 | $16M | Buy |
314,664
+36,766
| +13% | +$1.93M | 0.02% | 968 |
|
|
2017
Q2 | $14.1M | Sell |
277,898
-107,247
| -28% | -$4.99M | 0.01% | 1001 |
|
|
2017
Q1 | $15.5M | Buy |
385,145
+170,192
| +79% | +$7.64M | 0.01% | 969 |
|
|
2016
Q4 | $10.3M | Sell |
214,953
-55,504
| -21% | -$2.2M | 0.01% | 1195 |
|
|
2016
Q3 | $9.91M | Sell |
270,457
-68,587
| -20% | -$2.15M | 0.01% | 1201 |
|
|
2016
Q2 | $7.9M | Sell |
339,044
-38,234
| -10% | -$1.23M | 0.01% | 1327 |
|
|
2016
Q1 | $15.3M | Buy |
377,278
+36,177
| +11% | +$1.47M | 0.02% | 863 |
|
|
2015
Q4 | $21.1M | Buy |
341,101
+5,061
| +2% | +$273K | 0.02% | 748 |
|
|
2015
Q3 | $13.6M | Sell |
336,040
-469,521
| -58% | -$24.3M | 0.02% | 938 |
|
|
2015
Q2 | $46.4M | Buy |
805,561
+476,064
| +144% | +$30.3M | 0.05% | 459 |
|
|
2015
Q1 | $21M | Buy |
329,497
+12,247
| +4% | +$831K | 0.02% | 789 |
|
|
2014
Q4 | $19.6M | Buy |
317,250
+5,957
| +2% | +$294K | 0.02% | 892 |
|
|
2014
Q3 | $12.1M | Buy |
311,293
+79,721
| +34% | +$2.83M | 0.01% | 1187 |
|
|
2014
Q2 | $7.98M | Buy |
231,572
+4,310
| +2% | +$136K | 0.01% | 1570 |
|
|
2014
Q1 | $9.82M | Sell |
227,262
-123,954
| -35% | -$6.01M | 0.01% | 1266 |
|
|
2013
Q4 | $14M | Buy |
351,216
+78,177
| +29% | +$2.79M | 0.01% | 1031 |
|
|
2013
Q3 | $10.3M | Buy |
273,039
+23,184
| +9% | +$693K | 0.01% | 1113 |
|
|
2013
Q2 | $6.71M | Buy |
+249,855
| New | +$5.31M | 0.01% | 1374 |
|
Other funds holding IONS
BG
Credit Suisse's IONS Position: Q1 2024 in Review
Credit Suisse reduced its Ionis Pharmaceuticals (IONS) stake by 3.8% in Q1 2024, selling an estimated $344K and leaving 182,509 shares worth $7.91M. The position accounts for 0.01% of the portfolio, ranked #1039.
Credit Suisse first reported a position in IONS in Q2 2013 and has held it in 44 quarters since. The position peaked at $46.4M in Q2 2015. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2024.
- Credit Suisse held 182,509 shares of Ionis Pharmaceuticals worth $7.91M as of Q1 2024.
- Credit Suisse sold 7,213 Ionis Pharmaceuticals shares in Q1 2024, an estimated $344K.
- Ionis Pharmaceuticals made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1039 holding.
- Credit Suisse first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Ionis Pharmaceuticals position peaked at $46.4M in Q2 2015.
- 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.